Market Data 
Markets
Replies to post #192163 on Biotech Values
06/19/15 10:30 AM
06/22/15 12:44 PM
06/24/15 5:05 PM
07/01/15 10:24 AM
07/28/15 5:15 PM
08/05/15 2:54 PM
Loeb, whose firm has almost a 10 percent stake including amassed options it’s converting into stock, applauded the company’s recent spinoff of its Baxalta Inc. pharmaceutical business, and for announcing a succession plan for current CEO Robert Parkinson. Third Point, which oversees about $18 billion, said it has more than $2 billion in economic exposure to Baxter.
…Loeb described Baxter’s staggered board as “shareholder unfriendly and archaic,” where only a few directors are up for re-election each year, and its “odd voting structure that values shareholders individually rather than according to economic interest.”
11/03/15 9:22 AM
Debiotech SA…and Fresenius Medical Care, the world's largest provider of dialysis products and services, announced today they have entered into an exclusive partnership to develop a portfolio of state-of-the-art peritoneal dialysis (PD) technologies. This partnership will bring Debiotech's specialized expertise to the dialysis industry.
12/02/15 3:04 PM
AI
